MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Metrics to compare | MDWD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDWDPeersSector | |
---|---|---|---|---|
P/E Ratio | −9.5x | 1.8x | −0.5x | |
PEG Ratio | 0.20 | 0.03 | 0.00 | |
Price/Book | 6.4x | 1.2x | 2.6x | |
Price / LTM Sales | 10.5x | 1.3x | 3.3x | |
Upside (Analyst Target) | 62.4% | 230.5% | 43.4% | |
Fair Value Upside | Unlock | 27.3% | 7.1% | Unlock |